Mucosal healing and inflammatory bowel disease: Therapeutic implications and new targets

被引:20
|
作者
Otte, Megan Lynn [1 ]
Tamang, Raju Lama [2 ]
Papapanagiotou, Julia [2 ]
Ahmad, Rizwan
Dhawan, Punita
Singh, Amar B. [3 ]
机构
[1] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA
[2] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA
[3] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, 600 42nd Dewey, Omaha, NE 68118 USA
关键词
Inflammation; Injury; repair; Mucosal healing; Mucosal barrier; Therapeutics; Colitis; CHAIN FATTY-ACIDS; INTESTINAL BARRIER FUNCTION; FORMYL PEPTIDE RECEPTOR; REGULATORY T-CELLS; EPITHELIAL-CELLS; CROHNS-DISEASE; GUT MICROBIOTA; STEM-CELLS; IN-VIVO; MAINTENANCE THERAPY;
D O I
10.3748/wjg.v29.i7.1157
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Mucosal healing (MH) is vital in maintaining homeostasis within the gut and protecting against injury and infections. Multiple factors and signaling pathways contribute in a dynamic and coordinated manner to maintain intestinal homeostasis and mucosal regeneration/repair. However, when intestinal homeostasis becomes chronically disturbed and an inflammatory immune response is constitutively active due to impairment of the intestinal epithelial barrier autoimmune disease results, particularly inflammatory bowel disease (IBD). Many proteins and signaling pathways become dysregulated or impaired during these pathological conditions, with the mechanisms of regulation just beginning to be understood. Consequently, there remains a relative lack of broadly effective therapeutics that can restore MH due to the complexity of both the disease and healing processes, so tissue damage in the gastrointestinal tract of patients, even those in clinical remission, persists. With increased understanding of the molecular mechanisms of IBD and MH, tissue damage from autoimmune disease may in the future be ameliorated by developing therapeutics that enhance the body's own healing response. In this review, we introduce the concept of mucosal healing and its relevance in IBD as well as discuss the mechanisms of IBD and potential strategies for altering these processes and inducing MH.
引用
收藏
页码:1157 / 1172
页数:16
相关论文
共 50 条
  • [31] Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review
    Alimohammadi, Niloufar
    Koosha, Farzad
    Rafeian-Kopaei, Mahmoud
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (22) : 2668 - 2675
  • [32] Chemokines as Novel Therapeutic Targets for Inflammatory Bowel Disease
    Nishimura, Miyuki
    Kuboi, Yoshikazu
    Muramoto, Kenzo
    Kawano, Tetsu
    Imai, Toshio
    CONTEMPORARY CHALLENGES IN AUTOIMMUNITY, 2009, 1173 : 350 - 356
  • [33] THERAPEUTIC TARGETS FOR INFLAMMATORY BOWEL DISEASE: A PHEWAS APPROACH
    Kars, Meltem Ece
    Bao, Michelle
    Gettler, Kyle
    Stein, David
    Cho, Judy H.
    Itan, Yuval
    GASTROENTEROLOGY, 2024, 166 (05) : S1113 - S1113
  • [34] Eicosanoids in inflammatory bowel disease - Therapeutic implications
    Casellas, F
    Guarner, F
    CLINICAL IMMUNOTHERAPEUTICS, 1996, 6 (05): : 333 - 340
  • [35] Inflammatory bowel disease:: pathogenesis and targets for therapeutic interventions
    Panés, J
    ACTA PHYSIOLOGICA SCANDINAVICA, 2001, 173 (01): : 159 - 165
  • [36] Therapeutic implications of inflammasome in inflammatory bowel disease
    Khatri, Vishal
    Kalyanasundaram, Ramaswamy
    FASEB JOURNAL, 2021, 35 (05):
  • [37] New therapeutic targets in chronic inflammatory bowel diseases
    Cortot, A
    THERAPIE, 2004, 59 (01): : 77 - 81
  • [38] Inflammatory bowel disease and inflammatory molecules: Chickens, eggs and therapeutic targets
    Grimm, MC
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (09) : 935 - 937
  • [39] New treatment targets for inflammatory bowel disease?
    Herrlinger, K. R.
    Stange, E. F.
    INNERE MEDIZIN, 2025, 66 (01): : 55 - 63
  • [40] New immunomodulatory targets in inflammatory bowel disease
    Wittig, BM
    PROCEEDINGS OF THE 11TH INTERNATIONAL CONFERENCE ON ULCER RESEARCH, 2003, : 353 - 359